Egalet Corp., of Wayne, Pa., disclosed the end of its collaboration with Shionogi & Co. Ltd., of Osaka, Japan, for its abuse-deterrent, extended-release hydrocodone product. With the close of the partnership, Egalet gains worldwide rights to phase I candidate S-718632.